comparison the teraputic effect of pioglitazone and carnitine to metformin and carnitine in patients with non alcoholic fatty liver disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190701044062N3

Enrollment

Registered

2020-09-16

Start date

2019-10-22

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non alcoholic fatty liver disease (NAFLD). Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: For this group of patients, 1000 mg of carnitine and 30 mg of pioglitazone will be prescribed daily for 6 months. Drugs, especially carnitine, are available at diff

Eligibility

Sex/Gender

All

Age

17 Years to 50 Years

Inclusion criteria

Inclusion criteria: 17-50 years old Paitents with non alcoholic fatty liver disease who have been ruled out all known causes of fatty liver disease including alcohol, medications, viral hepatitis, autoimmune hepatitis and metabolic causes such as Wilson and hemochromatosis and etc.

Exclusion criteria

Exclusion criteria: Patients with liver disease such as viral hepatitis, autoimmune hepatitis, Wilson, hemochromatosis, liver cirrhosis, and PBC and PSC Patients who drink alcohol. Patients with renal Failure ( Creatinine > 1.5 mg/dl) Patients with known severe systemic disease and malignancy. Pregnancy or breastfeeding Patients with type 1 diabetes

Design outcomes

Primary

Measure	Time frame
Liver enzymes levels before and after carnitine and pioglitazone administration. Timepoint: At baseline and 3 months later and 6 months after the intervention. Method of measurement: Laboratory methods.;Ultrasound grade determination before and after carnitine and pioglitazone. Timepoint: At baseline and 6 months after intervention. Method of measurement: Perform liver ultrasound.;Liver enzymes levels before and after carnitine and metformin. Timepoint: At baseline and 3 months later and 6 months after the intervention. Method of measurement: laboratory methods.;Ultrasound grade determination before and after carnitine and metformin. Timepoint: At baseline and 6 months after intervention. Method of measurement: Perform liver ultrasound.	—

Measure

Time frame

Liver enzymes levels before and after carnitine and pioglitazone administration. Timepoint: At baseline and 3 months later and 6 months after the intervention. Method of measurement: Laboratory methods.;Ultrasound grade determination before and after carnitine and pioglitazone. Timepoint: At baseline and 6 months after intervention. Method of measurement: Perform liver ultrasound.;Liver enzymes levels before and after carnitine and metformin. Timepoint: At baseline and 3 months later and 6 months after the intervention. Method of measurement: laboratory methods.;Ultrasound grade determination before and after carnitine and metformin. Timepoint: At baseline and 6 months after intervention. Method of measurement: Perform liver ultrasound.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactManouchehr Khoshbaten

Tabriz University of Medical Sciences

mkhoshbaten@yahoo.com+98 41 1334 3010

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026